Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF) has announced that CEO Rob Ross, M.D., will participate in a fireside chat at the Cowen Fifth Annual IO Next Summit on November 15, 2021, at 12:45 p.m. ET. The session will be accessible via a live audio stream and archived webcast on the company's website.

Surface Oncology focuses on next-generation immunotherapies aimed at the tumor microenvironment, featuring clinical-stage programs like SRF617 and SRF388. The company partners with Novartis and GlaxoSmithKline for ongoing collaborations.

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the upcoming Cowen Fifth Annual IO Next Summit on Monday, November 15, 2021 at 12:45 p.m. ET.

The live audio and subsequent archived webcast of the fireside chat will be accessible from the Events & Presentations page of the company's website.

About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; preclinical). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:

Investors
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com

or

Stephen Jasper
Gilmartin Group
858-525-2047
stephen@gilmartinir.com

Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936

FAQ

What is the date and time of Surface Oncology's fireside chat at the Cowen Fifth Annual IO Next Summit?

The fireside chat is scheduled for November 15, 2021, at 12:45 p.m. ET.

Where can I listen to the Surface Oncology fireside chat?

The fireside chat can be accessed via live audio and archived webcast on Surface Oncology's Events & Presentations page.

Who is participating in the fireside chat at the Cowen Summit for Surface Oncology?

CEO Rob Ross, M.D., will participate in the fireside chat.

What is the focus of Surface Oncology's immunotherapy research?

Surface Oncology develops next-generation immunotherapies targeting the tumor microenvironment.

Which companies does Surface Oncology collaborate with?

Surface Oncology collaborates with Novartis and GlaxoSmithKline on specific immunotherapy programs.